跳至主要内容
临床试验/EUCTR2020-002726-84-IT
EUCTR2020-002726-84-IT进行中(未招募)1 期

ong-Term Safety and Efficacy Outcomes Following PreviouslyAdministered Short-Term Treatment with SHP607 in Extremely PrematureInfants - Footsteps

PREMACURE AB, A MEMBER OF SHIRE GROUP OF COMPANIES0 个研究点目标入组 25 人开始时间: 2021年5月24日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
25

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1.Subject was randomized into Study SHP607-202. Subjects who were
  • randomized, but did not complete Study SHP607-202 must be at least 12
  • 2.Written informed consents (and assents, if applicable) must be signed
  • and dated by the subject's parent(s)/legally authorized
  • representative(s) prior to any study-related procedures. The informed
  • consent and any assents for underage parents must be approved by the institutional review board (IRB)/independent ethics committee (IEC).
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Subjects are excluded from the study if the subject or subject's
  • parent(s)/legally authorized representative(s) is/are unable to comply
  • with the protocol or is/are unlikely to be available for long-term followup as determined by the investigator.

研究者

发起方
PREMACURE AB, A MEMBER OF SHIRE GROUP OF COMPANIES

相似试验